Keith A. Katkin
About Keith A. Katkin
Keith A. Katkin is a seasoned executive with extensive experience in the pharmaceutical industry, currently serving on the boards of Syndax Pharmaceuticals, Inc., and Emergent BioSolutions, Inc.
Keith A. Katkin’s Professional Titles
Keith A. Katkin has held the title of Chairman of the Board of Directors for Otic Pharma from 2015 to 2017. He was also the Principal Executive Officer and a member of the board of directors of Urovant Sciences Ltd from September 2017 until March 2020. Katkin served as the President and Chief Executive Officer of Avanir Pharmaceuticals, Inc. from 2007 to 2016. Currently, he is on the Board of Directors of Syndax Pharmaceuticals, Inc., and Emergent BioSolutions, Inc.
Keith A. Katkin’s Education and Expertise
Keith A. Katkin holds an M.B.A. from the Anderson School of Business at UCLA. He also earned a B.S. in Business and Accounting from Indiana University. In addition, Katkin is a certified public accountant, which adds a layer of financial acumen to his extensive business and leadership experience.
Keith A. Katkin’s Leadership Roles
Keith A. Katkin has held significant leadership roles in multiple pharmaceutical companies. He joined Avanir Pharmaceuticals in 2005 as Senior Vice President of Sales and Marketing, later becoming President and CEO. Katkin also served as Vice President, Commercial Development for Peninsula Pharmaceuticals, Inc. His extensive experience includes leadership positions at InterMune, Inc., Amgen, Inc., and Abbott Laboratories.
Keith A. Katkin’s Corporate Governance Experience
Keith A. Katkin has had substantial experience in corporate governance. He served on the board of Rigel Pharmaceuticals, Inc. until May 2022. His current board memberships include Syndax Pharmaceuticals, Inc. and Emergent BioSolutions, Inc., providing him with a broad perspective on the pharmaceutical and biotechnological sectors.
Keith A. Katkin’s Achievements
One of Keith A. Katkin's notable achievements includes leading the growth and ultimate sale of Avanir Pharmaceuticals to Otsuka Pharmaceutical Co., Ltd. for $3.5 billion. This underscores his ability to drive significant business growth and execute successful corporate transactions.